Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer

Lorenz Frehner; Simon Haefliger; Ferdinando Cerciello; Tobias Grob; Sabine Schmid

doi:10.1159/000533572

Case Reports in Oncology (Sep 2023)

Complete Response on Larotrectinib in NTRK2 Fusion-Positive Non-Small Cell Lung Cancer

Lorenz Frehner,
Simon Haefliger,
Ferdinando Cerciello,
Tobias Grob,
Sabine Schmid

Affiliations

Lorenz Frehner: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Simon Haefliger: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Ferdinando Cerciello: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Tobias Grob: Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
Sabine Schmid: Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

DOI: https://doi.org/10.1159/000533572
Journal volume & issue: Vol. 16, no. 1
pp. 871 – 877

Abstract

Read online

In patients with non-small cell lung cancer (NSCLC) harboring a fusion of the neurotrophic receptor kinase (NTRK) gene 1 or 3, treatment with tropomyosin kinase (TRK) inhibitors have shown promising results, however so far no data on efficacy of these agents in patients with NSCLC and NTRK2 fusion are available. We present a case of a female patient with NTRK2-positive NSCLC with a complete ongoing response on therapy with larotrectinib, suggesting efficacy of first-generation TRK inhibitors also in NTRK2-positive NSCLC.

Published in Case Reports in Oncology

ISSN: 1662-6575 (Online)
Publisher: Karger Publishers
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: http://www.karger.com/cro

About the journal

Abstract

Keywords